Viba Malaiyandi, MD
Board-Certified Dermatologist
I enjoy taking time to answer questions and counsel patients because I believe understanding is key to achieving long term positive results.
-
Education

Undergraduate Degree:
University of Toronto, Canada

Masters of Science:
University of Toronto School of Graduate Studies, Canada

Medical School:
St. George’s University School of Medicine, Grenada, West Indies

Dermatology Residency:
University of Toronto, Canada

Certificates
American Board of Dermatology
Fellow of the Royal College of Physicians of Canada
Professional Memberships
European Academy of Dermatology and Venereology
Ontario Medical Association
Canadian Medical Association
American Society of Dermatologic Surgery
American Academy of Dermatology
Canadian Dermatology Association
Achievements
Best Clinical Research, Dermatology Resident Research Day, University of Toronto: Validating Diagnostic Codes for Acne and Psoriasis (2014)
American Society for Dermatologic Surgery Preceptorship Award, University of California (2014)
Resident-Teaching Award, University of Toronto (2012)
Lillian Massey Treble Gold Medal, Victoria College, University of Toronto (2003)
Golden Key International Honour Society, Toronto Chapter (2001)
Publications

1. Ejaz A, Malaiyandi V, Kim WB, Rogalska T, Alhusayen R. Validating the diagnostic code for acne
in a tertiary care dermatology centre. Eur J Dermatol 2015 Oct 1; 25(5): 469-71. Epub 2015 Oct 30. PMID: 26518997 / doi: 10.1684/ejd.2015.2606
2. Malaiyandi V, Houle MC, Skotnicki-Grant S. Airborne allergic contact dermatitis from tylosin in pharmacy compounders and cross-sensitization to macrolide antibiotics. Dermatitis 2012 Sep-Oct; 23(5):227-30. PMID: 23010831
3. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 2007 Apr; 9(4):511-8. PMID: 17454707
4. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006 Oct; 15(10):1812-9. PMID: 17035386
5. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006 Apr; 11(4):400-9. PMID: 16402128
6. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variationfor smoking behaviors and nicotine dependence. Clin Pharmacol Ther 2005 Mar; 77(3):145-58. PMID: 15735609